GIS0 Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

GIS0 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	4/6
Financial Health	3/6
Dividends	5/6

Rewards

Trading at 62.9% below our estimate of its fair value

Earnings are forecast to grow 11.08% per year

Earnings grew by 1129.9% over the past year

Pays a reliable dividend of 3.26%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Gilead Sciences, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Merck KGaA

XTRA:MRK

€53.6b

Amgen

NasdaqGS:AMGN

US$143.0b

Sartorius

XTRA:SRT3

€14.4b

Price History & Performance

Summary of share price highs, lows and changes for Gilead Sciences
Historical stock prices
Current Share Price	US$12.67
52 Week High	US$12.84
52 Week Low	US$12.67
Beta	0.28
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-1.34%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	GIS0	DE Biotechs	DE Market
7D	n/a	0.4%	0.4%
1Y	n/a	-11.8%	13.1%

Return vs Industry: Insufficient data to determine how GIS0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how GIS0 performed against the German Market.

Price Volatility

Is GIS0's price volatile compared to industry and market?
GIS0 volatility
GIS0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.8%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: GIS0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine GIS0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	17,600	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GIS0 fundamental statistics
Market cap	€107.12b
Earnings (TTM)	€5.30b
Revenue (TTM)	€25.53b

20.2x

P/E Ratio

4.2x

P/S Ratio

Is GIS0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GIS0 income statement (TTM)
Revenue	US$28.74b
Cost of Revenue	US$6.24b
Gross Profit	US$22.50b
Other Expenses	US$16.53b
Earnings	US$5.97b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	4.80
Gross Margin	78.29%
Net Profit Margin	20.76%
Debt/Equity Ratio	130.8%

How did GIS0 perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

65%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/11 09:38
End of Day Share Price	2025/05/09 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 69 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research